Pieris Pharmaceuticals, Inc.
PIRSNASDAQHealthcare
$13.60
$-2.51(-15.58%)
Market Cap$17955264
P/E Ratio—
52W High$22.32
52W Low$6.2
Pieris Pharmaceuticals, Inc. (PIRS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PIRS · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 11, 2025EPS Actual
-$1.03
Revenue
—
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 11, 2025
After Market Close
✓ 1-Quarter EPS Beat Streak
PIRS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q4 FY2025 | Nov 11, 2025 | — | -$1.03 | — | — | — | — |
| — Q3 FY2025 | Aug 12, 2025 | — | -$0.86 | — | — | — | — |
| — Q2 FY2025 | May 13, 2025 | — | -$74.32 | — | — | — | — |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$4.00 | -$2.19 | +45.3% | — | $0.00B | — |
| ▼ Q3 FY2024 | Aug 14, 2024 | -$2.40 | -$2.76 | -15.0% | — | $0.00B | — |
| ▼ Q2 FY2024 | May 15, 2024 | -$0.12 | -$3.95 | -3191.7% | $0.00B | $0.00B | -95.9% |
| ▲ Q1 FY2024 | Mar 29, 2024 | -$9.60 | -$4.00 | +58.3% | $0.00B | $0.00B | -42.0% |
| — Q4 FY2023 | Nov 14, 2023 | -$8.80 | -$8.80 | +0.0% | $0.02B | $0.00B | +771.4% |
Q4 FY2025
Nov 11, 2025
EPS Actual
-$1.03
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 12, 2025
EPS Actual
-$0.86
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 13, 2025
EPS Actual
-$74.32
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$2.19
EPS Est.
-$4.00
EPS Surpr.
+45.3%
Revenue
—
Q3 FY2024
Aug 14, 2024Miss
EPS Actual
-$2.76
EPS Est.
-$2.40
EPS Surpr.
-15.0%
Revenue
—
Q2 FY2024
May 15, 2024Miss
EPS Actual
-$3.95
EPS Est.
-$0.12
EPS Surpr.
-3191.7%
Revenue
$0.00B
Q1 FY2024
Mar 29, 2024Beat
EPS Actual
-$4.00
EPS Est.
-$9.60
EPS Surpr.
+58.3%
Revenue
$0.00B
Q4 FY2023
Nov 14, 2023
EPS Actual
-$8.80
EPS Est.
-$8.80
EPS Surpr.
+0.0%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $-4.80 | $-4.80 | $-4.80 | 1 |
| Q3 FY2024 | $-4.00 | $-4.00 | $-4.00 | 1 |
| Q2 FY2024 | $-2.40 | $-2.40 | $-2.40 | 1 |
| Q1 FY2024 | $-4.80 | $-4.80 | $-4.80 | 1 |
| Q4 FY2023 | $-9.60 | $-9.60 | $-9.60 | 1 |
| Q3 FY2023 | $-8.80 | $-8.80 | $-8.80 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2025 | Nov 11, 2025 | — | $13.60 | — | — |
| — Q3 FY2025 | Aug 12, 2025 | — | $13.60 | — | — |
| — Q2 FY2025 | May 13, 2025 | — | $13.60 | — | — |
| ▲ Q4 FY2024 | Nov 13, 2024 | +45.3% | $16.12 | $16.10 | -0.12% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -15.0% | $16.41 | $16.75 | +2.07% |
| ▼ Q2 FY2024 | May 15, 2024 | -3191.7% | $11.22 | $11.37 | +1.34% |
| ▲ Q1 FY2024 | Mar 29, 2024 | +58.3% | $14.66 | $14.96 | +2.05% |
| ▲ Q4 FY2023 | Nov 14, 2023 | +0.0% | $19.20 | $20.00 | +4.17% |
Q4 FY2025—
Report Date
Nov 11, 2025
EPS Beat/Miss
—
Price Before
$13.60
Price After
—
Q3 FY2025—
Report Date
Aug 12, 2025
EPS Beat/Miss
—
Price Before
$13.60
Price After
—
Q2 FY2025—
Report Date
May 13, 2025
EPS Beat/Miss
—
Price Before
$13.60
Price After
—
Q4 FY2024-0.12%
Report Date
Nov 13, 2024
EPS Beat/Miss
+45.3%
Price Before
$16.12
Price After
$16.10
Q3 FY2024+2.07%
Report Date
Aug 14, 2024
EPS Beat/Miss
-15.0%
Price Before
$16.41
Price After
$16.75
Q2 FY2024+1.34%
Report Date
May 15, 2024
EPS Beat/Miss
-3191.7%
Price Before
$11.22
Price After
$11.37
Q1 FY2024+2.05%
Report Date
Mar 29, 2024
EPS Beat/Miss
+58.3%
Price Before
$14.66
Price After
$14.96
Q4 FY2023+4.17%
Report Date
Nov 14, 2023
EPS Beat/Miss
+0.0%
Price Before
$19.20
Price After
$20.00
Avg Beat Reaction+2.03%
Avg Miss Reaction+1.71%
Beat Rate3 / 8 quarters
Largest Move+4.17% (Q4 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PIRS ends December
Pieris Pharmaceuticals, Inc. (PIRS) most recently reported earnings on November 11, 2025 for Q4 FY2025, posting EPS of $-1.03 (in line with the analyst consensus of —). The next PIRS earnings date is expected around September 1, 2026.
Each quarter, investors track PIRS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PIRS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PIRS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PIRS earnings · 4 questionsPieris Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. PIRS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PIRS historically reports after market close (AMC).
PIRS earnings datewhen is PIRS earningsPIRS next earnings datewhen does PIRS report earningsPIRS earnings calendar
▸ Source: FMP · Pieris Pharmaceuticals, Inc. SEC filings · US GAAP · Pieris Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026